Source link : https://www.newshealth.biz/health-news/fda-approves-obe-cel-for-all/
The US Food and Drug Administration (FDA) has approved obecabtagene autoleucel, or obe-cel (AUTO1, Autolus Therapeutics) for the treatment of relapsed or refractory adult B-cell acute lymphoblastic leukemia (ALL). Approval of the CD19 chimeric antigen receptor T-cell therapy (CAR T) — which, according to Autolus, was specifically “designed to have a ‘fast-off’ kinetic” to minimize […]
Author : News Health
Publish date : 2024-11-08 22:43:48
Copyright for syndicated content belongs to the linked Source.